Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 56Head & Neck 8Thoracic 4Breast 4Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Inflammatory Breast Neoplasms 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Panitumumab × Breast × Clear all
NCT02593175 2025-11-06

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

M.D. Anderson Cancer Center

Phase 2 Completed
43 enrolled 8 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
47 enrolled 13 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01009983 2018-07-06

Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Wake Forest University Health Sciences

Phase 2 Terminated
14 enrolled 11 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00894504 2015-05-15

Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

SCRI Development Innovations, LLC

Phase 2 Completed
71 enrolled 7 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡